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miR-155-5p is a well-known oncogenic microRNA, showing frequent overexpression in
humanmalignancies, including breast cancer. Here, we show that highmiR-155-5p levels
are associated with unfavorable prognostic factors in two independent breast cancer
cohorts (CSS cohort, n = 283; and TCGA-BRCA dataset, n = 1,095). Consistently,
miR-155-5p results as differentially expressed in the breast cancer subgroups identified
by the surrogate molecular classification in the CSS cohort and the PAM50 classifier
in TCGA-BRCA dataset, with the TNBC and HER2-amplified tumors carrying the
highest levels. Since the analysis of TCGA-BC dataset also demonstrated a significant
association between miR-155-5p levels and the presence of mutations in homologous
recombination (HR) genes, we hypothesized that miR-155-5p might affect cell response
to the PARP-1 inhibitor Olaparib. As expected, miR-155-5p ectopic overexpression
followed by Olaparib administration resulted in a greater reduction of cell viability as
compared to Olaparib administration alone, suggesting that miR-155-5p might induce
a synthetic lethal effect in cancer cells when coupled with PARP-1-inhibition. Overall,
our data point to a role of miR-155-5p in homologous recombination deficiency and
suggest miR-155-5p might be useful in predicting response to PARP1 inhibitors in the
clinical setting.
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INTRODUCTION
Breast cancer (BC) is the most frequent cancer among women
worldwide, accounting for 13% of all cancer-related deaths (1).
Breast cancer is a heterogeneous disease that includes different
histological and molecular entities, clinical presentations, and
behaviors, which vary in prognosis and response to therapy. To
date, Oestrogen Receptor (ER), Progesterone Receptor (PgR),
human epidermal growth factor receptor 2 (HER2), and Ki67,
together with age, tumor size, histological grade, and lymph
node engagement still represent the most reliable markers
that provide prognostic information (2). Lately, microarray-
based gene expression studies have identified intrinsic breast
cancer subtypes of biological and, more importantly, clinical
relevance consisting of two oestrogen receptor positive (ER+)
subtypes, characterized by a relatively low (luminal A) and
high (luminal B) expression of proliferation-related genes, a
subtype enriched for HER2-amplified tumors (HER2-enriched),
a subtype characterized by the absence of ER, PgR expression
and HER2 amplification (Basal-Like) and a subtype ER +/–
and negative for, PgR, HER2, claudin 3, claudin 4, claudin
7, and E-cadherin (Claudin-low) (3–6). This information has
helped develop risk scores based on differential breast cancer
molecular profiles that are currently entering the clinical practice
to identify low-risk breast cancer patients who may avoid
adjuvant treatment (7). Nevertheless, even these classification
systems do not account for all the reported pathological and
clinical heterogeneity of breast cancer.
MicroRNAs (miRNAs) are small endogenous non coding
RNAs that fine-tune gene expression by post-transcriptional
silencing of target mRNAs. Among the plethora of miRNAs
that have been linked to human cancers, miR-155-5p (hsa-miR-
155-5p) stands out as prominent oncomiR showing frequent
overexpression in several hematological and solid tumors (8–12).
In breast cancer, miR-155-5p has been found mostly upregulated,
and associated with high-grade tumors, advanced stages, and
lymph node metastases as well as worse disease-free and overall
survival (13–22). At functional level, miR-155-5p validated
target genes potentially place miR-155-5p within several cancer-
related pathways encompassing cell proliferation, block of
differentiation, epithelial-mesenchymal transition (EMT), and
even DNA damage repair (DDR) (12, 23–26). However, these
relationships between miR-155-5p and breast cancer clinical
markers, such as ER and PgR status and tumor subtype,
along with its causal role in breast cancer development remain
controversial, likely due to limited patient sample sizes and
discrepancies among studies in terms of methodologies and
experimental models.
Herein, we report the results from the expression analysis of
hsa-miR-155-5p we performed in a large cohort of 283 breast
cancer patients with a complete median follow-up of 81 months
that likely enabled us to define robust relationships between miR-
155-5p and clinical parameters. We confirm that miR-155-5p
expression is associated with unfavorable prognostic indicators
in both our cohort and the TCGA-breast cancer dataset (TCGA-
BRCA). We also found that higher miR-155-5p levels correlate
with the basal-like subgroup followed by HER2-enriched tumors,
whereas lower levels characterize the Luminal A and Luminal
B tumors. Moreover, high miR-155-5p expression was found in
breast cancer tumors from the TCGA dataset carrying mutations
in HR genes. Lastly, we propose that miR-155-5p might play
a role in the response to the poly(ADP-ribose) polymerase-
1 (PARP-1) inhibitor Olaparib (AZD2281) which have been
receiving much attention as promising therapeutic strategy
beyond BRCA-mutant tumors, such as those with BRCAness and
homologous recombination deficiency (HRD).
MATERIALS AND METHODS
Study Design
We evaluated hsa-miR-155-5p expression in a retrospective
(prospectively collected) cohort of 283 breast cancer cases
with a median follow-up of 81-months (“Casa Sollievo
della Sofferenza”, hereafter CSS, cohort). The study was
conducted according to the REporting of tumor MARKer
Studies (REMARK) guidelines (27). Breast cancer samples
were collected at the Breast-Unit, IRCCS “Casa Sollievo della
Sofferenza.” Upon receipt from surgery, tissues from the bulk
of the tumor were sampled by the pathologist, then snap-frozen
in liquid nitrogen and stored at −80◦C. For legal reasons, only
one tumor specimen (∼50–100mg of frozen tissue in weight)
could be collected from each patient. Only women older than
18 years of age in were included in the study. All methods were
carried out following the international Helsinki Declaration
(7th rev, 2013, EU Directive 2004/23/EC) and Italian (D. Lgs.
30/06/2003, n. 196) regulations for research on patients. The
experimental procedures of this study were approved by the
Ethical Committee of the IRCCS “Casa Sollievo della Sofferenza”
(Prot. N◦ 140/CE). Prior written informed consent was obtained
from all patients in agreement with the experimental protocol
approved by the Ethical Committee. All patients received
either breast-conserving surgery or total mastectomy, plus
sentinel node biopsy, or complete axillary dissection. The post-
surgery treatments were performed according to the following
guidelines: AIOM (Associazione Italiana Oncologia Medica), St
Gallen, National Comprehensive Cancer Network (NCCN) and
American Society of Clinical Oncology (ASCO). Progression was
defined as evidence of loco-regional (recurrence) and/or distant
disease over 4 months from diagnosis and after curative-intent
surgical treatment. Clinical data were collected at each of the
scheduled follow-up times.
Clinicopathological Data
Pathological assessment consists of evaluating the histological
type, grade and stage. ER, PgR, Ki-67 labeling index, and
HER2 status were determined by immunohistochemistry (IHC).
Hormone receptor positive BCs, referred to as cases expressing
oestrogen (ER) or progesterone (PgR) receptors in ≥1%
of neoplastic cells by international guidelines (28), and
HER2-amplified BCs were established according to standard
recommendations (29). Of the 283 patients, 106 (38%) were
lymph node negative, and 177 (62%) lymph node positive.
Supplemental Table 1 summarizes descriptive statistics for the
283 cases from the CSS cohort analysed in this study. The median
Frontiers in Oncology | www.frontiersin.org 2 August 2020 | Volume 10 | Article 1415
Pasculli et al. miR-155-5p Relevance for Breast Cancer
age of the study population was 59 years (range, 29–89), and
the median tumor size was 2.5 cm (range, 0.5–11.0). Metastases
at diagnosis were found in 15 cases whereas among non-
metastatic patients (N = 268), 55 experienced disease progression
(Incidence Rate, IR 3.25 events per 100 PY), and 30 of them (IR
1.65 events per 100 PY) died for the disease.
Cell Lines, Culture Conditions, and
Reagents
In vitro assays were performed in a series of four breast
cancer cell lines, encompassing the molecular subtypes of TNBC,
which were as follows: MDA-MB-231 (claudin-low), MDA-MB-
436 (basal-like), MDA-MB-468 (basal-like), and MDA-MB-453
(LAR (Luminal-Androgen-Receptor) subtype). MDA-MB-436
cell line was used as experimental model of BRCA1-mutant cells
as carrying the pathogenic variant 5396+1G>A in the splice
donor site of exon 20 resulting in a BRCA1 truncated protein
(30). MDA-MB-436 (HTB-130, lot#63048503, p19), MDA-MB-
468 (HTB-132, lot#63226339, p340), and MDA-MB-453 (HTB-
131, lot#62959336, p348) cell lines were purchased from ATCC
(American Type Culture Collection). MDA-MB-231 (Cat No.
92020424, lot#11D011, p40) cell line was purchased fromECACC
(European Collection of Authenticated Cell Cultures). Culture
conditions were as follows: MDA-MB-231, MDA-MB-468, and
MDA-MB-453 were maintained in MEM w/o L-Gln, 10% FBS,
2mM L-Gln, 1XNEAA, whereas MDA-MB-436 were maintained
in MEM w/o L-Gln 10% FBS, 2mM L-Gln, 1XNEAA, 5mM
NaP∗, Human Insulin 10µg/mL, GSH 16µg/Ml. All cell lines
were grown in a 5% CO2 humidified incubator at 37
◦C. All cell
lines were mycoplasma tested by Hoechst DNA staining and PCR
by using N-GARDe Mycoplasma PCR kit (Euroclone).
The PARP-1 inhibitor Olaparib (AZD2281) was kindly
provided by AstraZeneca, and dissolved in DMSO as a stock
solution of 10 mg/mL.
RNA Isolation and Quantitative Reverse
Transcription Polymerase Chain Reaction
(RT-qPCR) Analysis
Total RNA from tissues and cells was isolated according to
standard TRIzolTM protocol (Invitrogen, Thermo Fisher Sc).
RNA samples from CSS cohort were selected as previously
described (31). To assess miR-155-5p expression levels in our
cohort of breast cancers, we applied a quantification method
with standard curve. Briefly, for both miR-155-5p (ID 002623,
Thermo Fisher Sc) and RNU48 (ID 001006, Thermo Fisher
Sc) endogenous control, standard curves were constructed by
plotting the threshold cycle (Ct) values against logarithm10 of
the copy number and fitting by linear least square regression.
For each sample, real-time PCR reactions were run in triplicate
on ABI PRISM 7900 HT Sequence Detection System (Thermo
Fis Sc). For tissue samples, miR-155-5p expression levels were
determined as the ratio of the miR-155-5p copy number to the
RNU48 copy number and then multiplied by 1000 for easier
tabulation [i.e., (hsa-miR-155-5p/RNU48)× 1,000] (31).
Statistical and Bioinformatics Analyses
Patients’ baseline characteristics were reported as median along
with interquartile range (IQR, i.e., first-third quartiles) or
frequencies and percentages for continuous and categorical
variables, respectively. Comparisons between miR-155-5p levels
and clinical pathological characteristics were assessed by Pearson
correlation with continuous variables and by the two-sample t-
test (or ANOVAmodel as appropriate) or Mann–WhitneyU-test
(or Kruskal–Wallis test when appropriate). In case of ANOVA
model, pairwise comparisons were assessed from statistical
contrasts (defined within the model) and computed p-values
were adjusted following the step-up Bonferroni method due to
Hochberg. In the case of the Kruskal–Wallis test, Dunn’s post-
hoc tests were carried out on each pair of groups and p-values
were adjusted using the Bonferroni method. The assumption
of normality distribution was checked by means of Q–Q plots
and Shapiro–Wilks test. As the distribution of miR-155-5p
expression levels in the CSS cohort was log-normal, all statistical
analyses that involved this cohort were performed on their
log-transformed values. Comparisons between distributions of
categorical variables were assessed by Chi-Square test. Time-to-
event analysis was performed in patients without metastases at
diagnosis by univariable proportional hazards Cox regression
models. Overall Survival (OS) was defined as the time between
the enrollment date and cancer-related death. Progression Free
Survival (PFS) was defined as the time between the enrollment
date and the tumor progression. Metastasis Free Survival (MFS)
was defined as the time between the enrollment date and the
development of distant metastases. For patients who did not
develop the event of interest, the endpoints (i.e., OS, PFS, and
MFS) were defined as the time between the enrollment date
and the date of the last available follow-up control. Incidence
rates (IR, i.e., mortality and disease progression rates) were
reported as number of events per 100 person-years (PY). A two-
sided p < 0.05 was considered for statistical significance. All
statistical analyses were performed using SAS Release 9.4 (SAS
Institute, Cary, NC, USA) and plots were produced using R
Foundation for Statistical Computing version 3.6. The PRISM
software (version 5, GraphPad, Inc.) was used tomake graphs and
statistical analysis of in vitro assays. Single nucleotide variations
(missense, frameshift, nonsense, and splicing SNV), copy number
variations (CNV), gene, and miRNA expression data and clinical
information concerning the TCGA-BRCA cohort, divided into
tumor without synchronous metastases and healthy individuals,
were retrieved from the NCI Genomic Data Commons (GDC,
https://portal.gdc.cancer.gov/) data portal as pre-processed raw
files. Germline point mutations in BRCA1 and BRCA2 genes
were retrieved from cBioPortal (TCGA PanCancer Atlas subset,
https://www.cbioportal.org/). Individuals were classified into
Prediction Analysis of Microarray 50 (PAM50) subgroups by
means of the R/Bioconductor TCGAbiolinks package. Files and
data were manipulated using the R Foundation for Statistical
Computing version 3.6. Clinicopathological characteristics of
these individuals were summarized in Supplemental Table 2.
The median age of the study population was 59 years (range, 27–
90) and themedian follow up was 12months (IQR 3–35months).
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Of the 1,095 patients, 991 (90%) were alive, and 104 (10%) died
for the disease.
Determination of Short-Term Olaparib IC50
(IC5072 h) by PrestoBlue
TM Viability Reagent
BC cells were seeded at 14,000 cells per well onto 96-well-
plates and treated with a series of 2-fold Olaparib serial dilutions
ranging from 230 to 1.8µM, or vehicle (DMSO), in a final
volume of 90 µL. For each treatment and vehicle condition,
six technical replicates were prepared. Moreover, for each cell
line, determination of Olaparib IC5072h was repeated in three
independent 96-well-plates at different times. Cell viability was
then evaluated after 72 h of treatment by PrestoBlue viability
reagent (Thermo Fisher Sc). Briefly, 10 µL of the ready-to-use
PrestoBlue Reagent were added directly to the medium. The
96-well-plates were incubated at 37◦C for 2 h, and fluorescence
was measured on a plate reader (Synergy HT Microplate Reader,
BioTek) at 560 nm. Cell viability was calculated as the percentage
of cells inhibited by the treatment as measured by the ratio
in fluorescence between Olaparib-treated and vehicle-treated
(DMSO) cells. The percentage of viable cells was plotted against
Log concentrations of Olaparib. Individual data points on dose-
response curves are shown as mean ± SD of n = 3 biological
replicates. The Olaparib IC5072h for BC cell lines, i.e., the
concentration of Olaparib causing a 50% reduction in cell
viability in a time-interval of 72 h, were as followed: MDA-
MB-436 IC5072h 25.8µM (95%CI: 24.52–27.15), MDA-MB-231
IC5072h 56.8µM (95%CI: 53.71–59.98), MDA-MB-468 IC5072h
33.81µM (95%CI: 31.24–36.60), and MDA-MB-453 IC5072h
175µM (95%CI: 160.8–190.6).
In vitro Transient Transfection of
miR-155-5p Mimic/Inhibitor and Olaparib
Treatment
To achieve transient overexpression or inhibition of miR-155-
5p before Olaparib treatment, BC cells were first seeded onto
96-well-plates at 14,000 cells/well and 6-well-plates at 4.1 ×
104 cells/well. Next, BC cell lines were transfected by using
50 nM mirVana miR-155-5p mimic (MC12601, Thermo Fisher
Sc.) ormirVanamiR-155-5p inhibitor (MH12601, Thermo Fisher
Sc.), and correspondent negative controls (mirVanaTM miRNA
Mimic, Negative Control #1 and mirVanaTM miRNA Inhibitor
Negative Control #1, respectively, Thermo Fisher Sc.) according
to Lipofectamine RNAiMAX forward transfection protocol
(Thermo Fisher Sc). For each condition, eight and two technical
replicates were prepared in each 96-well and 6-well-plate.
After 24 h from transfection, cell lines were treated with
correspondent Olaparib IC5072h, except for MDA-MB-453 cell
line, which was treated with a lower Olaparib dose (i.e.,
IC4072 h, 60µM) because showing higher sensitivity, in terms
of cell tolerance, to liposomes-mediated transfection. Next, cell
viability upon miR-155 modulation followed by 72-h exposure
to Olaparib was measured by PrestoBlueTM viability reagent as
described above.
To evaluate the true effects of miR-155-5p and Olaparib
combination on cell viability and rule out those related to vehicle-
and transfection procedures, experimental results are presented
as comparison between miR-155 overexpressing/downregulated
cells and control c(-) cells, treated with Olaparib or vehicle
(DMSO). Data are shown as mean ± SD of n = 4 biological
replicates (Student’s t-test, ∗p < 0.05, ∗∗p < 0.01; ∗∗∗p < 0.001).
To assess the extent of miR-155-5p overexpression/inhibition
by RT-qPCR, adherent cells were harvested by both 96-well-
plates and 6-well-plates, and processed for RNA isolation
as described above. For each cell line, miR-155-5p levels
in mimic/inhibitor-transfected cells were calculated as fold
change (2−11CT) to correspondent negative control c(–)-
transfected cells.
Western Blotting Analysis
Whole protein extracts from 6-well-plate seeded-cells were
obtained by RIPA buffer (Tris-HCl 10mMpH 7.5, NaCl 140mM,
Sodium deoxycholate 1%, sodium orthovanadate 1mM, SDS
0.1%, Sodium fluoride 1mM, EDTA 1mM, Triton X-100 1%,
1X Protease inhibitor), resolved by SDS-PAGE, and transferred
onto PVDF membranes. Primary antibodies for the bone-fide
miR-155-5p target C/EBPβ (sc150, Santa Cruz Biotechnology)
and normalizer Vinculin (#13901, Cell Signaling Tech) were
detected by species-specific secondary HRP-linked antibodies,
and revealed by using Pierce ECL 2 Substrate (Thermo Fisher
Sc.). Image acquisition was performed on ChemiDoc XRS (Bio-
Rad, Richmond, CA).
RESULTS
Surrogate Molecular Classification of the
CSS Cohort
Several genome-wide expression analyses have tried to identify
clinically relevant molecular breast cancer subtypes (3–6).
Among them, the PAM50 (4, 5) distinguishes five intrinsic
subtypes: luminal A, luminal B, basal-like, HER2-enriched, and
normal breast-like, characterized by different clinical behaviors.
However, due to a lack of reimbursement, multigene tests are not
readily available for all patients in many countries including Italy.
Consequently, the use of immunohistochemistry (IHC) based
biomarkers such as Ki-67 together with HER2 status has been
proposed to distinguish ER-positive breast cancer cases at high
risk of disease progression (i.e., bona fide Luminal B tumors)
from those at low risk of disease progression (i.e., bona fide
Luminal A tumors) (7). Instead, it is well established that HER2-
amplification or intense overexpression (IHC 3+) is associated
with worse prognosis in ER-positive BC patients. It is more
difficult to classify the risk of ER-positive HER2-negative tumors
because the prognostic performance of Ki-67 IHC staining shows
a high variability among studies and laboratories (7). In our
cohort, we evaluated two possible Ki-67 cut-offs: a 20% cut-
off, as proposed by AIOM Guidelines (https://www.aiom.it/wp-
content/uploads/2018/11/2018_LG_AIOM_Mammella.pdf), and
the median cut off value of Ki-67 calculated in our study
population (30%). As shown in Supplemental Table 3, only
a Ki-67 cut-off of <30% was able to distinguish patients at
low risk from patients at higher risk of disease progression
(PFS HR = 0.38; 95%CI = 0.16–0.90; P = 0.029), metastases
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development (MFS HR = 0.34; 95%CI = 0.14–0.79; P =
0.012) and death (OS HR = 0.11; 95%CI = 0.01–0.87; P
= 0.037) within the ER-positive subgroup. Thus, we defined
Luminal A (LUMA) tumors as ER-positive/PgR positive, and
HER2-negative with a low Ki-67 assessment (<30%), and
Luminal B (LUMB) tumors as ER/PgR positive either HER2-
positive or with a Ki-67 ≥ 30%. Overall, 94 cases (36%)
were classified as Luminal A, 98 cases (37%) as Luminal B
along with 34 HER2-amplified cases (13%), and 36 Triple
Negative Breast Cancer cases (TNBC) (14%). The 21 remaining
cases were not classified because HER2 or Ki-67 statuses
were unknown.
miR-155-5p Expression Is Associated With
Unfavorable Prognostic Indicators in Both
CSS Cohort and TCGA-BRCA Dataset
The expression of miR-155-5p [(hsa-miR-155-5p/RNU48) ×
1,000] was evaluated in 283 primary breast tumors. As shown
in Supplemental Table 4, miR-155 expression was associated
with unfavorable prognostic indicators including high tumor
grade (overall P = 0.0007; G2 vs. G3 P = 0.0053), reduced
expression of ER (r = −0.243; P = 0.0002) and PgR (r =
−0.240; P < 0.0001), and high Ki-67 expression (r = 0.215; P
= 0.0005). Overall, these data suggest that miR-155 increased
expression is associated with hormone receptor independency,
high proliferation rate, and poor differentiation. However, no
significant association was found with the pathological stage,
lymph node status, and metastases development. These results
were confirmed by the analysis of the TCGA-BRCA dataset
(Supplemental Table 5). Then, we evaluated the expression of
miR-155-5p across the surrogate molecular classification groups
of the CSS cohort (n = 262) and the PAM50 subgroups for
the TCGA-BRCA dataset (n = 505). In both cohorts, miR-
155-5p was differentially expressed among the subgroups (CSS
cohort P = 0.0008; TCGA-BRCA dataset P = 0.0005). In
particular, higher miR-155 expression was found in HER2-
amplified and TNBC subgroups, as compared with both Luminal
A (P = 0.012 and 0.013, respectively) and Luminal B (both
P = 0.0219) in the CSS cohort (Figure 1A). Accordingly, in
the TCGA-BRCA dataset, the highest level of miR-155 was
found in the basal-like subgroup followed by HER2-enriched
tumors, whereas lower levels were detected in the Luminal A
and Luminal B tumors. Pairwise comparison among groups
evidenced statistically significant differences in the Basal-like
subtype as compared with both Luminal A (P = 0.0001)
and Luminal B subtypes (P = 0.0001), whereas the HER2-
enriched subgroup showed significant differences only with the
Luminal A subtype (P = 0.0001; Figure 1B). No significant
associations were found between miR-155 expression and HER2
amplification/overexpression in neither CSS cohort nor TCGA-
BRCA dataset.
When we sought to determine putative associations of
miR-155 with clinical outcomes, no statistically significant
associations between miR-155 levels and patients’ survival
emerged from univariable Cox Regression analyses, in either
the total population or molecular subgroups of both CSS
cohort and TCGA-BRCA dataset. Moreover, no association was
found in the subgroups of CSS patients stratified according to
therapeutic regimens (chemotherapy, radiotherapy, and anti-
HER2 monoclonal antibodies; data not shown).
FIGURE 1 | miR-155-5p is differentially expressed within the molecular breast cancer subgroups. (A) miR-155-5p expression within the surrogate molecular
classification in CSS-cohort. High miR-155-5p expression was found in TNBC and HER2-amplified subgroups as compared with LUMA and LUMB tumors. (B)
miR-155-5p expression within molecular subgroups identified by PAM50 in TCGA-BRCA dataset. High miR-155-5p levels were found in the Basal-like subgroup as
compared with both Luminal A and Luminal B tumors, and in HER2-enriched subgroup as compared with Luminal A subgroup.
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miR-155-5p Is Differentially Expressed in
Breast Cancer From TCGA-BRCA Dataset
According to the Mutational Status of
Homologous Recombination Genes
miR-155-5p has been found to be epigenetically repressed by
wild type BRCA1 through its association with HDAC2 at
MIR155 gene promoter and such a regulation is impaired by
the R1699Q variant of BRCA1 (32). This, together with the
findings that high levels of miR-155-5p associate with the Basal
Like phenotype, a common feature of BRCA- mutated tumors,
spurred us to investigate whether miR-155-5p may be associated
with Homologous Recombination Deficiency (HRD), and thus
represents a typical trait of BRCAness. To test this hypothesis,
we selected those breast cancer cases for which the mutational
status of 24 genes involved in the Homologous recombination
pathway (Table 1) was available (n = 1,095 plus 104 normal
controls) from the TCGA-BRCA dataset. Of those tumors, 801
carried at least one mutation (indel, missense or CNV) in one
of the homologous recombination genes. Information about the
expression levels of miR155-5p was available for 793 out of 801
mutated tumors and 291 out of the 295 cases without mutation
in these genes (wt). Of the 793 mutated cases, 26 patients carried
germline mutations in BRCA1 or BRCA2 (germMut), while 763
carried somatic mutations in homologous recombination genes
(mutHR). Overall, 3,144 mutations were reported of which 91%
were CNV and 9% were SNP or indels (Supplemental Table 6).
The list of SNPs and indel mutations, together with their putative
functional relevance, is reported in Supplemental Table 7. As
shown in Figure 2A, miR-155 was increased in tumor samples
(Median 302.94, IQR = 184.62–536.70) as compared with
controls (n = 104) (Median = 129.96, IQR = 103.57–179.24;
P = 0.0001). Higher miR-155 expression was found in the
mutHR subgroup (Median = 446.600, IQR = 198.82–596.07)
as compared with the wtHR subgroup (Median = 246.55, IQR
= 148.43–419.62; P < 0.0001). The fact that no statistically
significant differences were found for the germBRCA subgroup
(Median= 446.60, IQR= 186.68–656.97) as compared with both
wt (P = 0.134) and mutHR (P = 1.00), might be ascribed to the
low number of germMut cases (n= 26; Figure 2A). Furthermore,
the distribution of PAM50 subtypes differed significantly among
the groups, with Basal-like and HER2-amplified tumors being
more frequent in mutHR (83 and 55, respectively) as compared
with wt (8 and 1, respectively; P = 0.0001). In the mutHR
subgroup (Figure 2B), miR-155 was differentially expressed
among the intrinsic molecular subtypes with higher expression
in the Basal-Like (Median = 660.07, IQR = 296.79–1,262.98)
and HER2-enriched (Median = 423.58, IQR = 251.10–653.04)
tumors as compared with Luminal subtypes (LUMA Median =
252.87, IQR= 178.77–435.31, and LUMBMedian= 292.89, IQR
TABLE 1 | Summary of mutations detected in the 24 homologous recombination genes evaluated in the TCGA-BRCA dataset.
Gene symbol Ensembl ID Cytoband Copy Number Variation Frameshift mutation SNP
Deletions Amplifications Deletion Insertion Missense Non sense Splice site
ARID1A ENSG00000117713 1p36.11 172 19 10 3 13 14 3
ATM ENSG00000149311 11q22.3 157 34 1 0 15 5 2
ATRX ENSG00000085224 Xq21.1 21 18 2 0 39 3 1
BAP1 ENSG00000163930 3p21.1 140 11 1 1 9 1 0
BARD1 ENSG00000138376 2q35 47 36 0 0 0 0 0
BLM ENSG00000197299 15q26.1 14 92 1 0 15 1 0
BRCA1 ENSG00000012048 17q21.31 89 40 4 0 12 5 2
BRCA2 ENSG00000139618 13q13.1 86 73 5 0 18 3 1
BRIP1 ENSG00000136492 17q23.2 11 233 0 1 9 1 1
CHEK1 ENSG00000149554 11q24.2 157 25 0 0 2 0 0
CHEK2 ENSG00000183765 22q12.1 24 39 0 0 6 1 0
FANCA ENSG00000187741 16q24.3 64 40 0 0 8 0 0
FANCD2 ENSG00000144554 3p25.3 25 97 0 1 8 2 0
FANCE ENSG00000112039 6p21.31 31 66 0 0 3 0 0
FANCF ENSG00000183161 11p14.3 24 56 0 1 2 0 0
FANCG ENSG00000221829 9p13.3 18 56 0 0 3 0 0
FANCL ENSG00000115392 2p16.1 7 59 0 0 1 0 1
MRE11 ENSG00000020922 11q21 89 54 0 0 0 0 0
NBN ENSG00000104320 8q21.3 19 150 0 0 5 1 0
PALB2 ENSG00000083093 16p12.2 12 42 0 0 5 1 0
RAD50 ENSG00000113522 5q31.1 37 31 0 1 8 1 0
RAD51 ENSG00000051180 15q15.1 100 21 0 0 2 0 0
RAD51B ENSG00000182185 14q24.1 89 52 0 0 2 0 1
WRN ENSG00000165392 8p12 51 39 1 0 8 0 0
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FIGURE 2 | miR-155-5p expression is associated with mutations in HR genes and basal-like phenotype. (A) Higher miR-155-5p levels were detected in tumors
carrying mutations in HR genes. Statistically significant differences were found among controls with either germline BRCA1/2 mutated tumors (germBRCA), HR
mutated (mutHR) or non HR mutated tumors (wt). High miR-155-5p expression was found in both germBRCA and mutHR tumors as compared with the wild type (wt)
subgroups. (B) In mutHR tumors, miR-155-5p is differentially expressed according to PAM50 classification. Higher miR-155-5p levels were found in Basal-like and
HER2 tumors as compared with the Luminal A subtype, and in the HER2-amplified tumors as compared with Luminal A subtype.
FIGURE 3 | (A) miR-155-5p endogenous expression levels are significantly increased in the BRCA1mut MDA-MB-436 cell line as compared to the other wtBRCA-
TNBC cell lines. miR-155-5p was quantified by RT-qPCR and normalized using RNU48 as endogenous control. Data are presented as fold increase over the
expression levels of MDA-MB-231 and were derived from 6 biological replicates (Student’s t-test, **p < 0.01). (B) Olaparib similarly affects cell viability of basal-like
TNBC cell lines independently of BRCA-status. Growth curves of MDA-MB-231, MDA-MB-436, MDA-MB-468, and MDA-MB-453 (TNBC cell lines) were construed
following 72 h of treatment with a range of 2-fold serial dilutions of Olaparib compound (230–1.8µM) and cell viability assessment by PrestoBlueTM Reagent. The
percentage of viable cells was plotted against Log-transformed Olaparib concentrations. Data are presented as mean (±SD) of three independent experiments.
= 211.76–511.78; P < 0.0001; Figure 1B). Overall, these data
indicate that miR-155 expression may represent a hallmark of
homologous recombination deficiency (HRD).
miR-155-5p May Indirectly Affect Cell
Response to PARP-1 Inhibitor Olaparib
PARP-1 inhibitor Olaparib has been initially approved as
monotherapy for the maintenance treatment of adult patients
with platinum-sensitive relapsed BRCA-mutated (germline or
somatic) high-grade ovarian cancer (33). More recently, results
from the OlympiAD Phase 3 clinical trial indicate that Olaparib
is also effective in BRCA1 or BRCA2 mutated HER2-negative
metastatic breast cancer (34, 35). Our findings that high levels
of miR-155-5p associate with the presence of mutations at HR
genes prompted us to investigate whether miR-155-5p may affect
the response to the PARP inhibitor Olaparib to some extent.
To this aim, we selected four breast cancer cell lines of TNBC,
including the BRCA1mutant cell line MDA-MB-436 (basal-like),
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and the BRCA1 wild type lines with BRCA1 allelic loss but
normal transcript levels MDA-MB-468 (basal-like), MDA-MB-
231 (claudin-low) and MDA-MB-453 (LAR-subtype). We did
find that miR-155-5p endogenous levels were significantly
elevated in mutBRCA1 MDA-MB-436 cells compared to the
other cell lines (Figure 3A), suggesting the role of this BRCA1
pathogenic variant in abrogating negative regulation of miR-
155-5p (30, 32). Interestingly, we also observed that, when we
tested a wide range (see section Materials and Methods) of
Olaparib concentrations that reduced cell viability significantly
in a short time-interval of 72 h (IC5072), both basal-like TNBC
cell lines encountered a 50% reduction of viability upon Olaparib
treatment at similar doses independently of BRCA1 status
(MDA-MB-436, 25.80µM, 95%CI = 24.52–27.15; MDA-MB-
468 33.81µM 95%CI = 31.24–36.60) (Figure 3B). Next, to
test the hypothesis that miR-155-5p might affect response to
Olaparib, we ectopically overexpressed miR-155-5p in the less-
responsive wt BRCA1 cell lines (MDA-MB-453, MDA-MB-
231, and MDA-MB-468), and treated them at correspondent
IC5072h, with the exception of MDA-MB-453 cell line, for
which we chose a lower Olaparib dose (i.e., IC4072 h, 60µM)
because showing reduced tolerance to transfection procedures
compared to the other cell lines. The ectopic overexpression
of miR-155-5p itself induced a very significant decrease in
cell viability in all cell lines compared to control (c(–)) cells.
Moreover, when we treated both miR-155-5p overexpressing
and control cells with Olaparib compound, we did observe a
further reduction of cell viability, indicating that Olaparib and
miR-155-5p may cooperate, and severely impair the survival
of cancer cells (Figures 4A–C). Nevertheless, no alterations
in Olaparib cell sensitivity were observed upon miR-155-5p
inhibition in MDA-MB-436 (Figure 4D), suggesting that miR-
155-5p regulatory role may be necessary but not sufficient
for determining Olaparib sensitivity. The efficacy, as well
as functionality of miR-155-5p overexpression/inhibition, was
checked by both RT-qPCR and western blot analyses of
its bone-fide target C/EBPβ protein levels (Figures 5A–D,
Supplemental Figure 1).
FIGURE 4 | miR-155-5p effects on cell sensitivity to Olaparib. Cell viability was assessed by PrestoBlueTM reagent after induced overexpression in (A) MDA-MB-231,
(B) MDA-MB-468, and (C) MDA-MB-453 or inhibition in (D) MDA-MB-436 of miR-155-5p by mirVana miR-155-5p mimic or inhibitor followed by Olaparib
administration for 72 h. Data are presented as percentage of viable cells calculated in each condition (Olaparib vs. Vehicle) with respect to vehicle-treated
c(–)-transfected cells, and represent the mean (±SD) of four independent experiments (Student’s t-test, ***p < 0.001, ns = not significant).
Frontiers in Oncology | www.frontiersin.org 8 August 2020 | Volume 10 | Article 1415
Pasculli et al. miR-155-5p Relevance for Breast Cancer
Alterations of C/EBPβ Isoforms Abundance
May Mediate the Growth Inhibitory Effect
of miR-155-5p Coupled With Olaparib
As mentioned above, we evaluated the protein levels of miR-
155-5p bona-fide target C/EBPβ (36) by western blot to ensure
that ectopic modulation of miR-155-5p endogenous levels in the
transfected-cell lines was functional. C/EBPβ (CCAAT/enhancer-
binding protein) is a well-known transcription factor playing
a central role in controlling the growth and differentiation
of normal mammary gland, and it is produced in three
isoforms through alternative usage of different start codons:
the transcriptional activators liver activating protein 1 and 2
(LAP1 and LAP2), and the transcriptional inhibitor LIP, which
can inhibit LAPs-mediated gene activation (36). The analyses
of C/EBPβ protein levels in our cell lines showed a decreased
level of the LIP isoform in miR-155-5p overexpressing cells
compared to control cells, in both Olaparib- and vehicle-
treated cells (Figures 5A–C), demonstrating the functionality
of enforced miR-155-5p overexpression, and likely explaining
the decrease in cell viability we observed after miR-155-5p
overexpression. More interestingly, we noticed that, together
with the miR-155-5p-mediated LIP reduction, a marked increase
in LAP2 isoform in the claudin-low MDA-MB-231 cell line
was induced specifically by Olaparib administration (Figure 5A).
Since the smaller LAP2 isoform is considered to be the most
transcriptionally active of the C/EBPβ isoforms, it is likely that its
overexpression coupled with LIP downregulation, resulting in a
LIP:LAP imbalance, severely impairs cell proliferation. We could
not appreciate significant differences in MDA-MB-436 cell line,
although transfection appeared to be successful, probably due to
high C/EBPβ basal levels in this cell line, as shown by negative
control (c(–))-transfected cells (Figure 5D).
DISCUSSION
miR-155-5p is one of the best conserved and multifunctional
miRNA involved in several physiological processes, such as
proliferation, cell cycle, apoptosis, and differentiation (8–12).
Altered expression ofmiR-155-5p has been found to be associated
with hematopoietic lineage differentiation, immune response,
inflammation, and tumorigenesis (8–12). Several studies suggest
a role of miR-155-5p in breast cancer development and
progression. However, its putative role as a biomarker is still
controversial, likely due to limited patient sample sizes and
discrepancies among studies in terms of methodologies and
experimental models (13–22).
FIGURE 5 | Evaluation of efficacy and functionality of miR-155-5p overexpression/inhibition. miR-155-5p expression levels and western blot analyses of C/EBPβ
protein levels in (A) MDA-MB-231, (B) MDA-MB-468, (C) MDA-MB-453, and (D) MDA-MB-436. miR-155-5p expression levels are presented as fold increase
(2−11CT ) with respect to correspondent negative control c(–)-transfected cells, in the presence of Olaparib or vehicle, and represent the mean (±SD) of four
independent experiments (Student’s t-test, *p < 0.05, **p < 0.01; ***p < 0.001).
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The primary aim of our study was the evaluation of miR-
155-5p expression in a large cohort of breast cancer cases
with a median follow up of 81 months. Our results were
then validated in the TCGA-BRCA dataset. Consistently with
previous reports, miR-155-5p expression was associated with
negative prognostic factors including reduced expression of
hormone receptor, high histological grade, and proliferation
index measured by Ki67 expression in both our cohort and
TCGA-BRCA dataset. Indeed, when we evaluated miR-155-5p
expression within the subgroups identified by the surrogate
molecular classification in the CSS cohort, and the intrinsic
molecular classification in TCGA-BRCA dataset, the highest
levels of expression were found in the TNBC and Basal-
like subgroups followed by HER2-amplified tumors and the
lowest expression in the Luminal subgroups. Overall, these
data support the oncogenic role of miR-155-5p in deregulating
cell proliferation and differentiation within the hormone-
independent breast cancer subtypes. No associations were
found with lymph node status and metastases development
(Supplemental Tables 4, 5), as well as miR-155-5p did not
correlate with patient’s survival in univariable Cox regression
analyses in both cohorts. These data rule against the role of
miR155 as prognostic biomarkers in breast cancer. Nevertheless,
the small number of TNBC (n = 34) and HER2 (n = 36)
cases in our cohort, and the absence of information about
PFS and MFS in the publicly available TCGA-BRCA dataset
cannot completely exclude such a role in these breast cancer
subgroups. Thus, this result should be further evaluated in
retrospective or prospective studies with a specific focus on
these subgroups.
Breast cancers with loss-of-function mutations in BRCA1
or BRCA2 genes are deficient in the HR (Homologous
Recombination) pathway that manages the repair of DNA DSBs
(Double Strand Breaks); hence, they are exquisitely sensitive
to poly(ADP ribose) polymerase (PARP) inhibitors (37). This
sensitivity to PARP inhibition derives from the synthetic lethality
of cells with defective homologous recombination-mediated
DNA repair to toxic replication intermediates generated on
chromatin by PARP “trapping” (38). Preclinical studies and
clinical trials in breast, ovarian cancer, and other cancers
have shown the PARP inhibitors efficacy in BRCA1- and
BRCA2-mutant patients (38–40). This led in 2014 to the
approval by drug regulatory agencies of the PARP inhibitor
Olaparib for the treatment of patients with recurrent ovarian
cancer and BRCAs mutations (41). Encouraging results with
Olaparib have also been obtained in patients with metastatic
breast cancer-bearing germline BRCAs mutations (40–42). The
randomized, phase 3 OlympiAD trial showed that among
germline BRCA mutated patients affected by ER-positive HER2-
negative metastatic TNBC, median progression-free survival was
significantly longer with oral Olaparib monotherapy than with
standard chemotherapy (34). This has finally led to Olaparib
FDA-approval in January 2018 for gBRCA1/2+ HER2–breast
cancers in the metastatic setting (35).
Although germline BRCA (germBRCA) mutations still remain
the best clinical biomarkers for response to PARP inhibitor
therapy (34, 43), genetic and epigenetic inactivation of other
components of the homologous recombination apparatus can
lead to HRD in sporadic cancers, broadly termed BRCAness (44).
These alterations can occur in the form of germline mutations in
HRR-associated genes, such as PALB2, FANCM, CHECK2, and
RAD51C/D (44) or somatic mutations including ATM, BAP1,
CDK12 (44) so that numerous studies are currently testing the
possibility to apply mutational signatures to the prediction of
PARP-inhibitors responsiveness (45, 46). BRCAness and HRD
also involve methylation of the BRCA-promoter, which appears
to be most common in TNBCs (47, 48). Breast tumors with
BRCA1 methylation also show the higher histological grade, like
that of BRCA1-mutated tumors (49). Additional contributors to
HRD involve copy number alterations (CNA), and early research
has revealed that the basal-like subtype of breast cancer has
higher numbers of gains/losses, while the Luminal B subtype has
a more frequent high-level DNA amplification (50).
Thus far, a few miRNAs have emerged as determining
the BRCAness phenotype and, therefore, the response to
PARP inhibition-based therapy (51, 52). miR-155-5p has been
previously found to increase the tumor mutation load and
promote the so-called “mutator phenotype” in inflammation-
driven tumors due to the combined targeting of cell-cycle
regulators and DNA repair enzymes (25, 26). Moreover,
miR-155-5p expression has been found to be epigenetically
controlled by BRCA1 through the recruitment of histone
deacetylase 2 (HDAC2) at the MIR155 gene promoter (32)
that ultimately leads to transcriptional silencing. In human cell
lines, BRCA1-deficient cells showed 50-fold higher miR-155-
5p levels compared with those with functional BRCA1. Finally,
the transient overexpression of BRCA1 protein reduces the
expression of miR-155-5p and, in clinical samples, miR-155-
5p levels were 2- to 6-fold higher in BRCA1-mutant tumors
compared to wt BRCA1 tumors.
For these reasons, we wondered whether miR-155-5p might
correlate with defects in HR genes and represent a putative trait
of BRCAness in the breast cancer of Triple Negative subtype
(TNBC). Overall, we found that defects in the homologous
recombination genes are a common feature of breast cancer, with
73% of cases in the TCGA-BRCA dataset carrying at least one
germline or somatic mutation in HR genes. Almost all Basal
Like and HER2-associated tumors were HR mutated. When we
tested the putative association of miR-155-5p with the presence
of mutations in Homologous Recombination genes, we were not
surprised to find that miR-155-5p did show higher expression
levels in themutHR subgroup rather than in the wtHR subgroups
in the TCGA Breast cancer dataset.
Next, we assessed the capability of miR-155-5p to alter the
response to the first-in-class PARP inhibitor Olaparib (AZD2281)
of four BC cell lines, differing in both molecular subtype and
BRCA1 status. As expected, the MDA-MB-436 cells, representing
a BRCA1-mutant basal-like TNBC cell line, showed a higher
sensitivity to a short-term (72 h) treatment with Olaparib alone
(IC5072h 25.80µM, 95%CI = 24.52–27.15) compared to the
other cell lines. In addition, we also observed that, independently
of BRCA-mutational status, the second basal-like TNBC cell
line MDA-MB-468, carrying normal levels of BRCA1 transcript
despite allelic loss, and low expression of ATM, did show a
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high sensitivity to Olaparib (IC5072h 33.81µM, 95%CI = 31.24–
36.60), consistent with previous findings supporting this cell’s
BRCAness phenotype (49), and confirming that HR deficiency
might be exploited to get a cancer cell response beyond BRCA-
mutations. Then, when we enforced miR-155-5p overexpression
in MDA-MB-231, MDA-MB-468, and MDA-MB-453 cell lines,
we observed a significant decrease in cell viability following miR-
155-5p overexpression alone in all cell lines. Interestingly, miR-
155-5p-induced overexpression, followed by Olaparib exposure,
resulted in an increased sensitivity to PARP inhibition and a
further reduction in cell viability.
In order to determine the functionality of modulated miR-
155-5p in our in vitromodels, we analysed the protein expression
levels of the transcriptional factor C/EBPβ, known to be one
of bone-fide targets of miR-155-5p that plays an important
role in regulating the balance between cell differentiation and
proliferation in the mammary gland, according to the differential
expression pattern of its isoforms. In particular, C/EBPβ has been
recognized as core factor of the TGFβ cytostatic program, being
essential for the induction of p15INK4b and the repression of c-
MYC (53), and mediator of Ras-induced senescence (54). The
association of C/EBPβ defects with breast cancer progression
has been mostly attributed to aberrant levels of LIP isoform
that, once elevated, may antagonize the transcriptional activities
of LAPs and thus confer a growth advantage to cancer cells
(55–58). Consistently with these data, ectopic overexpression
of miR-155-5p in our cell lines showed to reduce the levels
of the inhibitory LIP isoform in miR-155-5p-overexpressing
cells with respect to control-transfected cells in both Olaparib-
and vehicle-treated cells, thus demonstrating the functionality
of synthetic oligos, and likely explaining the decrease in cell
viability we observed after miR-155-5p mimic transfection
(Figures 5A–C). Interestingly, we could detect a significant
increase in the C/EBPβ LAP2 isoform protein level as a specific
pattern of Olaparib treatment compared to vehicle in claudin-
low MDA-MB-231 cells (Figure 5A). We might speculate that
the decreased cell viability achieved in this cell line by miR-
155-5p overexpression and Olaparib combination was a result
of an enforced cell growth inhibitory effect exerted by LAP2
regulated genes and PARP inhibition. Moreover, since increased
LAP2 was observed specifically in Olaparib-treated cells, we
cannot rule out that the specific Olaparib action may go beyond
PARP enzymes inhibition, and stimulate additional pathways
toward growth inhibition. Hence, these data raise the question of
whether increasing instead of inhibiting miR-155-5p in different
cancer settings may enhance PARPi efficacy. Indeed, previous
reports have already demonstrated the capability of miR-155-
5p of boosting the anticancer immune response by targeting
anti-inflammatory factors and immune checkpoints, including
CTLA4 and PD-L1 [reviewed in (59)], something that may be of
relevance for putative PARPi and Immunocheckpoints Inhibitors
(ICI) combined therapies (60).
However, our results as well as the in vitro evidence that
inhibition of miR-155-5p in BRCA1mut MDA-MB-436 cell line
did not affect the higher sensitivity to PARP inhibition support
the idea that several mechanisms underlie sensitivity to PARPi,
and the understanding of the BRCAness as well as considering
the specific BC subtype context warrants further investigation.
In conclusion, the analysis of two independent breast cancer
cohorts corroborates the oncogenic role for miR-155-5p. Indeed,
increased miR-155-5p expression was associated with loss of
hormone receptor, reduced differentiation, and high proliferation
rate. Consistently, miR-155-5p was differentially expressed in
breast cancer molecular subgroups, with the highest expression
in basal-like and HER2-related tumors. In addition, higher
miR-155-5p expression was found in breast cancer cases from
the TCGA dataset carrying mutations in HR genes. Lastly, we
propose that a novel mechanism of synthetic lethality mediated
by PARP inhibition and miR-155-5p may promote cancer cell
death, and suggest miR-155-5p as an additional trait of the
BRCAness phenotype.
Currently, several scoring systems aimed to identify HRD
tumors are under investigation. These systems showed some
predictive value in metastatic breast cancer patients treated
with platinum derivatives (61). By using a high-depth whole-
genome sequencing approach, Davies H. et al. developed a
tool, they called HRDetect, as a predictor of BRCA1 and
BRCA2 deficiency based on mutational signatures (62). Such
a technology was able to identify six different mutational
signatures and classify BRCA1/2-deficient tumors correctly
with 98.7% sensitivity. In addition, in a cohort of 560
individuals with BC, HRDetect identified 22 tumors with
somatic loss-of-BRCA1 or BRCA2 and 47 tumors with functional
BRCA1/2 deficiency, none of which had mutations detected
with standard analysis (61). However, to date, HRDetect
has not been correlated yet with therapeutic responses to
PARPi. Another recent study evaluated a novel gene expression
signature-generating algorithm to predict therapeutic response
to PARPi (63). Our results indicate that, together with
mutation and gene expression signatures, miRNA expression
analysis may aid in evaluating the competency of homologous
recombination, and thus eventually increase the ability to
predict response to PARPi, in order to ultimately identify
additional breast cancer patients eligible for PARP-inhibition
including regimens.
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